BACKGROUND:Endoscopic papillary large balloon dilation with biliary sphincterotomy (EPLBD + EBS) is safe and effective in patients with large common bile duct (CBD) stones. However, data on long-term outcomes after EPLBD + EBS remain limited. We sought to prospectively evaluate the long-term recurrence of CBD stones after EPLBD + EBS and to identify the associated factors. METHODS: We conducted an extended follow-up of a previous randomized trial (2009-2011) comparing the outcomes of 30- versus 60-s large balloon dilation. A total of 106 trial participants undergoing successful CBD stone clearance by EPLBD + EBS were prospectively followed up for up to 4 years (range 19-48 months). Various risk factors were analysed to assess predictors of long-term recurrence of stones. RESULTS:Recurrent CBD stones appeared in 8/106 (7.5 %) patients during a mean follow-up of 30.5 ± 5.5 months. The mean diameter of CBD was significantly higher in the recurrence versus non-recurrence group (2.0 ± 4.9 vs 1.6 ± 0.9 cm, p = 0.008). Multivariate analysis revealed that CBD diameter was the only predictor significantly associated with the long-term recurrence of stones (odds ratio 1.2, p = 0.01). CONCLUSIONS:EPLBD + EBS is associated with a low rate of long-term CBD stone recurrence. However, the risk is significantly higher in patients with a more dilated CBD.
RCT Entities:
BACKGROUND: Endoscopic papillary large balloon dilation with biliary sphincterotomy (EPLBD + EBS) is safe and effective in patients with large common bile duct (CBD) stones. However, data on long-term outcomes after EPLBD + EBS remain limited. We sought to prospectively evaluate the long-term recurrence of CBD stones after EPLBD + EBS and to identify the associated factors. METHODS: We conducted an extended follow-up of a previous randomized trial (2009-2011) comparing the outcomes of 30- versus 60-s large balloon dilation. A total of 106 trial participants undergoing successful CBD stone clearance by EPLBD + EBS were prospectively followed up for up to 4 years (range 19-48 months). Various risk factors were analysed to assess predictors of long-term recurrence of stones. RESULTS: Recurrent CBD stones appeared in 8/106 (7.5 %) patients during a mean follow-up of 30.5 ± 5.5 months. The mean diameter of CBD was significantly higher in the recurrence versus non-recurrence group (2.0 ± 4.9 vs 1.6 ± 0.9 cm, p = 0.008). Multivariate analysis revealed that CBD diameter was the only predictor significantly associated with the long-term recurrence of stones (odds ratio 1.2, p = 0.01). CONCLUSIONS: EPLBD + EBS is associated with a low rate of long-term CBD stone recurrence. However, the risk is significantly higher in patients with a more dilated CBD.
Entities:
Keywords:
Endoscopic retrograde cholangiopancreatography; Large balloon dilation; Sphincterotomy; Stone recurrence
Authors: Tae Hyeon Kim; Jin Hong Kim; Dong Wan Seo; Dong Ki Lee; Nageshwar D Reddy; Rungsun Rerknimitr; Thawee Ratanachu-Ek; Christopher J L Khor; Takao Itoi; Ichiro Yasuda; Hiroyuki Isayama; James Y W Lau; Hsiu-Po Wang; Hoi-Hung Chan; Bing Hu; Richard A Kozarek; Todd H Baron Journal: Gastrointest Endosc Date: 2015-07-29 Impact factor: 9.427
Authors: G Stefanidis; N Viazis; D Pleskow; S Manolakopoulos; L Theocharis; C Christodoulou; N Kotsikoros; J Giannousis; S Sgouros; M Rodias; A Katsikani; R Chuttani Journal: Am J Gastroenterol Date: 2010-11-02 Impact factor: 10.864
Authors: Gregorios A Paspatis; Jean-Marc Dumonceau; Marc Barthet; Søren Meisner; Alessandro Repici; Brian P Saunders; Antonios Vezakis; Jean Michel Gonzalez; Stine Ydegaard Turino; Zacharias P Tsiamoulos; Paul Fockens; Cesare Hassan Journal: Endoscopy Date: 2014-07-21 Impact factor: 10.093
Authors: J J Bergman; E A Rauws; P Fockens; A M van Berkel; P M Bossuyt; J G Tijssen; G N Tytgat; K Huibregtse Journal: Lancet Date: 1997-04-19 Impact factor: 79.321